Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17329206 | 1.00 | PRMT1 (0.55) | PRMT1CA12CA1CA2CA5A | |
| SCHEMBL20296965 | 0.89 | MEN1 (0.59) | LMNAMAPTMEN1KMT2ARORC | |
| SCHEMBL18709367 | 0.89 | TSHR (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL18709336 | 0.89 | CA12 (0.55) | CA12CA1CA2CA9LMNA | |
| SCHEMBL20296961 | 0.89 | TSHR (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL20296990 | 0.89 | CA12 (0.55) | CA12CA1CA2CA9LMNA | |
| SCHEMBL18709402 | 0.89 | MEN1 (0.59) | LMNAMAPTMEN1KMT2ARORC | |
| SCHEMBL18687086 | 0.88 | MEN1 (0.51) | MEN1KMT2ARORC | |
| SCHEMBL18709404 | 0.88 | MEN1 (0.51) | MEN1KMT2ARORC | |
| SCHEMBL18709246 | 0.88 | LMNA (0.45) | LMNAGAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630939-B2 | Derivative of homoserine lactone, and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | claimed |
| US-20150368217-A1 | Derivative of Homoserine Lactone, and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-12-24 | — | — | US | claimed |
| EP-2955174-A1 | DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2015-12-16 | — | — | EP | claimed |
| US-9630939-B2 | Derivative of homoserine lactone, and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9630939-B2 | Derivative of homoserine lactone, and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20150368217-A1 | Derivative of Homoserine Lactone, and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-12-24 | — | — | US | disclosed |
| US-20150368217-A1 | Derivative of Homoserine Lactone, and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-12-24 | — | — | US | disclosed |
| EP-2955174-A1 | DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2015-12-16 | — | — | EP | disclosed |
| EP-2955174-A1 | DERIVATIVE OF HOMOSERINE LACTONE, AND PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368217-A1 | Derivative of Homoserine Lactone, and Preparation Method and Use Thereof | LSS, HES1, SOS1 | PRMT1 1595/4885CA12 4484/4885CA1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.